SANTA CLARA, Calif., Feb. 8, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited to present the results of a key QTinno® performance study at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), to be held in Dallas, March 3-5, 2011.
The study, entitled "Intelligent Automated ECG Extraction from Continuous 12-Lead Holter Recordings Reduces Measurement Variability in Thorough QT Studies," was completed in collaboration with physician scientists from a global pharmaceutical partner. Continuous 24-hour ECG recordings (Holters) are commonly used in cardiac safety drug studies. At present, the user visually selects three 10 second ECGs from the recording within 5 minutes of each designated study time point, a labor-intensive approach that is prone to error and variability. NewCardio has developed a novel ECG selection algorithm that evaluates the entire 10-minute window around the designated time point and selects the lowest noise and most stable ECGs in the window. The study chosen for presentation at the ASCPT meeting shows NewCardio's automated ECG selection method yields substantially more accurate and precise data than visual ECG selection. Moreover, the accuracy gain from automated ECG selection is fully additive to the accuracy gain delivered by QTinno itself.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We are pleased to have this opportunity to present our results on automated ECG selection at the annual ASCPT meeting. This is a prestigious and well-attended forum, and gives us an excellent opportunity to share our latest QTinno improvements and innovations with scientists and professionals from academia, drug regulatory bodies, clinical trial service providers, and